key: cord-0899813-5m4ybd1v authors: Li, Yumin; Han, Xiaoyu; Alwalid, Osamah; Cui, Yue; Cao, Yukun; Liu, Jia; Gu, Jin; Wang, Lixia; Fan, Yanqing; Shi, Heshui title: Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: a retrospective study date: 2020-07-03 journal: Diabetes Res Clin Pract DOI: 10.1016/j.diabres.2020.108299 sha: 0770d41b4d73d1e9eb65f0ad3519cee9180e3467 doc_id: 899813 cord_uid: 5m4ybd1v Abstract Aims To investigate the clinical characteristics, laboratory findings and high- resolution CT (HRCT) features and to explore the risk factors for in-hospital death and complications of coronavirus disease 2019 (COVID-19) patients with diabetes. Methods From Dec 31, 2019, to Apr 5, 2020, a total of 132 laboratory-confirmed COVID-19 patients with diabetes from two hospitals were retrospectively included in our study. Clinical, laboratory and chest CT data were analyzed and compared between the two groups with an admission glucose level of ≤11mmol/L (group 1) and >11mmol/L (group 2). Logistic regression analyses were used to identify the risk factors associated with in-hospital death and complications. Results Of 132 patients, 15 died in hospital and 113 were discharged. Patients in group 2 were more likely to require intensive care unit care (21.4% vs. 9.2%), to develop acute respiratory distress syndrome (ARDS) (23.2% vs. 9.25%) and acute cardiac injury (12.5% vs. 1.3%), and had a higher death rate (19.6% vs. 5.3%) than group 1. In the multivariable analysis, patients with admission glucose of >11 mmol/l had an increased risk of death (OR: 7.629, 95%CI: 1.391-37.984) and in-hospital complications (OR: 3.232, 95%CI: 1.393-7.498). Admission d-dimer of ≥1.5 μg/mL (OR: 6.645, 95%CI: 1.212-36.444) and HRCT score of ≥10 (OR: 7.792, 95%CI: 2.195-28.958) were associated with increased odds of in-hospital death and complications, respectively. Conclusions In COVID-19 patients with diabetes, poorly-controlled blood glucose (>11mmol/L) may be associated with poor outcomes. Admission hyperglycemia, elevated d-dimer and high HRCT score are potential risk factors for adverse outcomes and death. Since the late of December 2019, a newly recognized novel coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly in China and around the world [1] . According to the report of World Health Organization on May 18, 2020, the total number of confirmed cases has risen sharply to 4,618,821 in more than 110 countries, with 311,847 (6.8%) deceased cases [2] . The population is generally susceptible to SARS-CoV-2 infection. However, several epidemiological studies had described that older adults and those with certain underlying diseases are more vulnerable to the disease, with diabetes mellitus (DM) being one of the most frequent comorbidities [1, 3, 4] . It has been estimated that 463 million adults are living with diabetes worldwide [5] , and those individuals are at a higher risk of infection and may have worse outcomes than the population without diabetes once infected [6, 7] . Previous studies demonstrated that diabetes was an independent risk factor for mortality in patients with Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), Pandemic Influenza A (H1N1) and Middle East Respiratory Syndrome coronavirus (MERS-CoV) [8] [9] [10] . Angiotensin-converting enzyme 2 (ACE2) is a functional receptor for SARS-CoV that is expressed in pancreatic islets, among others, which can aggravate the diabetes progression [11] . Notably, SARS-CoV-2 can also bind to the target cells through ACE2 and the affinity is 10 to 20 times higher than SARS-CoV [12] . Therefore, COVID-19 patients with diabetes might have higher disease severity and poor prognosis. However, the available information regarding COVID-19 patients with diabetes is inadequate at present. Hence, this study aimed to analyze the detailed clinical characteristics, laboratory findings and HRCT features and to explore the risk factors for inhospital death and complications of COVID-19 patients with diabetes. This was a retrospective cohort study carried out at two hospitals in Hubei province, China (Wuhan Union hospital of Tongji Medical College and Jinyintan Hospital). All patients with pre-existing diabetes who were diagnosed with SARS-CoV-2 pneumonia according to WHO interim guidance [13] , and those who died or were discharged from hospital between Dec 31, 2019, and Apr 5, 2020, were included in this study. The study was approved by the institutional review boards of the two hospitals. Informed consent was waived for this retrospective study. All admission data were obtained from patients' electronic medical records and were reviewed by two physicians (Jin Gu and Yue Cui). Information extracted included demographic data, exposure history, comorbidities, symptoms, treatments, in-hospital complications, outcomes, laboratory results and chest CT images. Based on the fasting blood glucose (FBG) levels on admission, two groups of patients were designated: group 1 (with FBG ≤11mmol/L) and group 2 (with FBG >11mmol/L). The primary outcomes included an intensive care unit (ICU) entry and inhospital death. The secondary outcomes were any in-hospital complications, including SARS-CoV-2-related ARDS, acute cardiac injury, acute kidney injury and secondary infection. ARDS was diagnosed based on the WHO guidance for COVID-19 [13] . Acute cardiac injury was identified if the serum highsensitivity cardiac troponin I level was above the upper limit of the 99 th percentile reference [14] . Acute kidney injury was diagnosed according to the clinical practice guidelines of KDIGO [15] . Secondary infection was identified if the patient had a positive culture of a new pathogen obtained from the lower respiratory tract specimens or blood samples after admission [14] . Chest CT scans were obtained using either of the following CT scanners: SOMATOM Definition AS+, SOMATOM Spirit, or SOMATOM Perspective (Siemens Healthineers, Forchheim, Germany). The parameters used for the scanning protocol were as described in our previous study [16] . All initial CT images were assessed by three radiologists (Heshui Shi, Jin Gu and Yanqing Fan) with more than 15 years of experience in thoracic radiology. The predominant three CT findings included ground glass opacity (GGO), crazy-paving pattern and consolidation, and any other CT characteristics were described on the basis of previous studies on COVID-19 patients [ 16， 17] . The extent of pulmonary involvement of all of these abnormalities in each lung lobe was evaluated using a semi-quantitative scoring system [18] . CT score for each of the three findings at each of the 5 lung lobes was scored from 0 to 5, with a total score of 0-25. Each lobe was scored as follows: 0, no involvement; 1, ≤5% involvement; 2, 6%-25% involvement; 3, 26%-49% involvement; 4, 50%-75% involvement; 5, >75% involvement. The Kolmogorov-Smirnov test was used to check the normality. Data were expressed as the mean ± SD, median (IQR) and n (%) for normally, nonnormally continuous variables and categorical variables, respectively. Differences between two groups stratified by FBG were assessed using independent-sample Student's t test, Mann-Whitney test, χ² test, or Fisher's exact test, as appropriate. Univariate and multivariate logistic regression models were used to explore the risk factors associated with in-hospital death and complications. A two-sided p value <0.05 was considered statistically significant. Analyses were performed using SPSS software version 21 (IBM, Chicago, IL, USA). From Dec 31, 2019, to Apr 5, 2020, a total of 154 consecutive confirmed COVID-19 patients with diabetes were admitted to hospital. Of these, 12 were excluded due to the lack of serum glucose test results and 10 were excluded because of missing CT images or other key information in their medical records. Table 1 . For the study cohort, the median age was 65 years (IQR, 57-71) and 70 (53%) patients were male. 130 patients (98.5%) were type 2 diabetes and the median disease duration was 8.5 years (IQR, 4-11.75). The most common symptoms at onset were fever (107, 81.1%) and cough (87, 65.9%), followed by shortness of breath (42.4%) and sputum (35.6%). The median time from onset of symptoms to hospital admission was 10 days (IQR,7.0-16.0). More than half of the patients had at least one other comorbidity, with hypertension being the most common (64.4%), followed by cardiovascular (13.6%) and cerebrovascular diseases (9.1%). Among 132 patients, 39 (29.3%) patients received high flow nasal cannula oxygen therapy, 10 (7.6%) patients needed noninvasive respiratory support and 5 (3.8%) patients required endotracheal intubation. In addition, most of the patients received antiviral (99.2%) and antibiotic treatments (85.6%), and some patients have taken corticosteroids (29.5%), intravenous immunoglobulin (22.7%) and antifungal agents (11.4%). Compared with group1, patients in group 2 were more likely in need of systematic corticosteroid treatment, and had more fever, more sputum, longer disease duration and lower oxygen saturation, but had no significant differences in age, gender and some other characteristics (Table 1) . On admission-laboratory test results of all patients and the subgroups are presented in Table 2 All patients had abnormal CT imaging features as presented in Table 3 . According to the semi-quantitative scoring system, the median total CT score of the pulmonary involvement was 11.5 (IQR, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Compared with group 1, patients in group 2 had higher total CT score (14.5 [IQR, (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) vs. 9.5 [IQR, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] ; p = 0.010) (Figure 1 , F). CT score of the left upper lobe and bilateral lower lobes in group 2 patients were also greater than patients in group 1. There were no significant differences in baseline CT characteristics mentioned above. (Table 1) . Compared with group 1, patients in group 2 had a higher death rate (19.6% vs. 5.3%, p = 0.010), were more likely to require ICU care (21.4% vs. 9.2%, p = 0.048) and to have more in-hospital complications, including ARDS (23.2% vs. 9.25, p = 0.027) and acute cardiac injury (12.5% vs. 1.3%, p = 0.010). The risk factors associated with in-hospital death and complications are shown in Supplemental Table S1 . According to univariable analysis, the admission glucose, absolute lymphocyte count and d-dimer were associated with an increased risk of in-hospital death and complications. Total CT score of the pulmonary involvement, white blood cell count, albumin, LDH, myoglobin, high-sensitivity troponin I and procalcitonin were also associated with odds of in-hospital complications. Considering the relatively small number of in-hospital deaths (n=15) and complications (n= 31) in our study and to avoid overfitting of the model, we have chosen age, hypertension, total CT score of the pulmonary involvement, The median age of COVID- 19 [20] . Fever and cough were the most common symptom, which were consistent with previous reports [1, 3] . A recent multi-centered study showed that patients with FBG >10 mmol/L had multiple organ injury and a higher mortality rate than individuals with FBG levels from 3.9 to 10 mmol/L [19] . Similarly, in our study, patients with poorly-controlled FBG (>11mmol/L) had a greater incidence of acute cardiac injury, ARDS, and ICU entry, and a higher death rate than those with FBG ≤11 mmol/L. Additionally, a previous study reported that the plasma glucose level was an independent predictor for morbidity and mortality in SARS [8] . The present study showed that FBG of >11mmol/l was associated with an increased risk of death and complications in COVID-19 patients with diabetes. Similarly, a large cohort study by Kornum et al. [21] found that the admission FBG of >11mmol/L was a predictor for mortality in type 2 diabetic patients with community-acquired pneumonia (CAP). It was proposed that hyperglycemia may impair the normal endothelial function, hinder phagocytosis, delay the chemotaxis and reduce the microbiocidal capacity [22] [23] [24] . These abnormalities are prone to progress when the glucose level is greater than 11 mmol/L and can be improved by better glycemic control [22] [23] [24] . A recent publication on COVID-19 patients showed that although glucose level was higher on admission, it subsequently decreased, while it continued to increase in deceased patients [25] . Therefore, timely blood glucose testing and better glycemic control play a key role in COVID-19 patients' prognosis. As described in recent studies [1, [26] [27] [28] , coagulation abnormalities were common in severe COVID-19 patients, and were marked by elevated d-dimer concentrations. In our study, d-dimer of ≥1.5 μg/mL was associated with higher odds of death, similar to a previous report in 191 . The state of hypoxia in severe pneumonia can lead to a hypercoagulable state of the blood by activating the exogenous coagulation pathway, and can also stimulate thrombus formation by increasing the blood viscosity [29] . In addition, chronic hyperglycemia can cause vascular injury, oxidative stress and inflammation, which can lead to the formation of atherosclerosis and thrombus [30] . Therefore, severe SARS-CoV-2 infection with diabetes is more likely to cause coagulopathy and resultant poor outcome. The present study found that the HRCT score of ≥10 was associated with increased odds of in-hospital complications. CT was an important inspection tool for COVID-19 and the score of the lesions involvement of the lung was correlated with histopathology [31]. In our study, patients with FBG of >11 mmol/L had a significantly higher CT score than those with FBG of ≤11 mmol/L. The present study has several limitations. First, this was a retrospective study, and the findings might be limited by the small sample size. Second, some laboratory results were missing in the electronic medical records, which may have led to a selection bias when identifying the risk factors for adverse outcomes. Third, this study did not assess the non-diabetic patients, since there have been numerous descriptive studies on the clinical and imaging characteristics of the general population. In conclusion, our study suggested that COVID-19 patients with poorlycontrolled FBG (>11mmol/L) had worse outcomes. Admission FBG of >11mmol/L was a risk factor for death and complications in COVID-19 patients with diabetes. Elevated d-dimer and HRCT score also contributed to the adverse outcomes. Our findings may provide useful information for the management of this special population and guide the strategies for more targeted intervention to improve the prognosis. Data are expressed as n (%) or mean (SD) or median (IQR). The p values reflect comparisons between group 1 and group 2. Supplemental Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Coronavirus disease 2019 (COVID-19) situation report e 119 Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study. The Lancet Respiratory Medicine International Diabetes Federation. IDF diabetes atlas. 9th ed. Brussels: IDF Pulmonary complications of diabetes mellitus Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China KDIGO clinical practice guidelines for acute kidney injury Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study CT Features of Coronavirus Disease 2019 (COVID-19) Pneumonia in 62 Patients in Wuhan, China Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome-evaluation with thin-section CT Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Preexisting Type 2 Diabetes Clinical characteristics of 2019 novel coronavirus infection in China Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care Juhan-Vague I. Hemobiology, vascular disease, and diabetes with special reference to impaired fibrinolysis